Related Experiment Video
Updated: May 6, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Integrating QSAR-Machine Learning, Biochemical Assays, and Molecular Dynamics for the Discovery of JAK2 Inhibitors in
Duangjai Todsaporn1, Kamonpan Sanachai2, Nattanit Suddee3
1Department of Biochemistry, Faculty of Science, Center of Excellence in Structural and Computational Biology, Chulalongkorn University, Bangkok 10330, Thailand.
Abstract:
Cervical cancer remains a major global health challenge, where dysregulated JAK2 signaling constitutes a key molecular driver. Nevertheless, selective small-molecule JAK2 inhibitors for HPV-positive cervical cancer are still limited. Here, we integrated biochemical assays, QSAR-machine learning, and molecular dynamics simulations to identify potent JAK2 inhibitors. A series of naphthalene-based derivatives, including hydroxynaphthalenamide and phosphorylated dihydronaphthylamide analogs, were evaluated for cytotoxicity in HeLa cells and JAK2 kinase inhibition. Several compounds exhibited selective cytotoxicity with minimal activity toward normal fibroblasts, among which 2q and 2s showed low-nanomolar JAK2 inhibition and strong apoptosis induction through suppression of the JAK2/STAT3/STAT5 pro-tumorigenic signaling pathway. To accelerate hit identification, a QSAR-machine learning (QSAR-ML) framework was employed to prioritize 13 newly designed derivatives. Among three ensemble boosting models, the Categorical Boosting (CB) model demonstrated the strongest predictive capability, achieving a high R2 of 0.955 for the training set and a low RMSE of 0.156 for the test set. This model successfully identified five active candidates with strong prediction-experiment agreement (MAPE = 2.6-14.4%), with D4 and D13 meeting drug-likeness criteria and displaying potent nanomolar JAK2 inhibition. Finally, 1-μs molecular dynamics simulations revealed that hydrophobic contacts and hydrogen bonding cooperatively stabilize these inhibitors within the JAK2 ATP-binding pocket. Collectively, these findings establish a QSAR-ML-guided strategy for accelerating JAK2 inhibitor discovery and highlight naphthalene-based scaffolds as promising leads for targeted cervical cancer therapy.
Insights
Researchers developed novel naphthalene-based compounds as selective JAK2 inhibitors for cervical cancer. A QSAR-machine learning model accelerated the discovery of potent drug candidates, showing promise for targeted therapy.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Oncology
Background:
- Cervical cancer is a significant global health issue driven by dysregulated Janus Kinase 2 (JAK2) signaling.
- Existing small-molecule JAK2 inhibitors are limited for HPV-positive cervical cancer.
Purpose of the Study:
- To identify potent JAK2 inhibitors for cervical cancer using an integrated approach.
- To develop a QSAR-machine learning (QSAR-ML) framework for accelerating drug discovery.
Main Methods:
- Biochemical assays and cytotoxicity evaluations in HeLa cells.
- QSAR-ML modeling, including ensemble boosting (Categorical Boosting model).
- Molecular dynamics simulations to analyze inhibitor binding to JAK2.
Main Results:
- Naphthalene-based derivatives, particularly 2q and 2s, showed selective cytotoxicity and low-nanomolar JAK2 inhibition.
- The QSAR-ML model achieved high predictive accuracy (R2=0.955, RMSE=0.156) and identified promising candidates like D4 and D13.
- Molecular dynamics revealed stable binding of inhibitors within the JAK2 ATP-binding pocket through hydrophobic and hydrogen bonding interactions.
Conclusions:
- A QSAR-ML-guided strategy effectively accelerates the discovery of JAK2 inhibitors.
- Naphthalene-based scaffolds represent promising leads for developing targeted therapies against cervical cancer.
- The identified compounds induce apoptosis by suppressing the JAK2/STAT3/STAT5 pathway.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity

